Coherus BioSciences

• Booth: 4113

Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that can expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs. For additional information, please visit www.coherus.com.

 Press Releases

• Toripalimab Program (Apr 26, 2021)
  https://www.coherus.com/immuno-oncology/toripalimad-program/

• UDENYCA® (pegfilgrastim-cbqv) Website (Apr 26, 2021)
  https://www.udenyca.com

• Coherus COMPLETE™ Website (Apr 27, 2021)
  https://www.coheruscomplete.com

• Coherus COMPLETE™ Overview Brochure (Apr 27, 2021)
  https://biogenericsinc-my.sharepoint.com/:b:/g/personal/rkelmar_coherus_com/EVt1ZYSLoHVLuVPv_jMghcAB_OgW6IhPiVyw5mdbpLdMEg?e=O5qvBG

• UDENYCA® (pegfilgrastim-cbqv) Healthcare Professional Brochure (Apr 27, 2021)
  https://biogenericsinc-my.sharepoint.com/:f:/g/personal/rkelmar_coherus_com/EsgLj45aSuREjOhrN7L_wtgBIQg6YENeWnuwqHiKAmZe1g?e=gn494b

 Products